Sanofi to invest $474M annually on mRNA vaccine R&D

By The Science Advisory Board staff writers

June 30, 2021 -- Sanofi will spend approximately 400 million euros ($474 million U.S.) to accelerate the research and development (R&D) of messenger RNA (mRNA) vaccines.

The company will accelerate vaccine work through its newly launched vaccines mRNA Center of Excellence, which will consist of 400 employees from sites in Massachusetts and France working to deliver next-generation mRNA vaccines against unmet diseases.

The teams will focus on R&D, digital, and chemistry, manufacturing and controls (CMC) of mRNA vaccines in both locations. By 2025, Sanofi hopes to have six clinical vaccine candidates.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.